Recro Pharma (REPH) Stock Price, News & Analysis

Company Overview

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.47 to $2.11
• 52-Week Range: N/A
• Volume: 141,800 shs
• Average Volume: 126,298 shs
• Market Capitalization: $117.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

REPH Stock Analysis - Frequently Asked Questions

How were Recro Pharma's earnings last quarter?

Recro Pharma, Inc. (NASDAQ:REPH) announced its earnings results on Tuesday, March, 1st. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03. Recro Pharma had a negative trailing twelve-month return on equity of 56.66% and a negative net margin of 15.15%.

What other stocks do shareholders of Recro Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Recro Pharma investors own include Corbus Pharmaceuticals (CRBP), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), SCYNEXIS (SCYX), Gilead Sciences (GILD) and Bristol Myers Squibb (BMY).

Company Calendar

• Last Earnings: 3/01/2022
• Today: 6/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:REPH
• CIK: 1588972
• Web: www.recropharma.com
• Phone: (770) 534-8239
• Fax: 484-395-2471
• Employees: 185
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.37 million
• Net Margins: -15.15%
• Pretax Margin: -15.09%
• Return on Equity: -56.66%
• Return on Assets: -11.14%

Debt

• Debt-to-Equity Ratio: 2.27
• Current Ratio: 3.24
• Quick Ratio: 2.74

Sales & Book Value

• Annual Sales: $75.36 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.90 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 56,424,000
• Free Float: 48,412,000
• Market Cap: $117.93 million
• Optionable: Optionable
• Beta: 1.08